Switching to Apixaban After Gastrointestinal Bleeding on Rivaroxaban
Evidence-Based Rationale
- The American College of Chest Physicians recommends that in patients with prior gastrointestinal bleeding, apixaban or dabigatran 110 mg bid may be preferable as they are the only NOACs not associated with an increased risk of gastrointestinal bleeding compared with warfarin, with a strong recommendation for NOACs over VKA in eligible AF patients 1, 2
- Apixaban demonstrates the lowest bleeding risk among all DOACs, with significantly less major bleeding compared with warfarin in patients at high risk of bleeding 1, 2
- The risk of bleeding may be lower with apixaban than with other DOACs, based on indirect comparisons and cancer-associated thrombosis studies 3, 4
Practical Implementation
- The American College of Cardiology recommends standard apixaban dosing of 5 mg twice daily, but dose reduction to 2.5 mg twice daily is indicated if the patient meets ≥2 of the following criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 5
- The European Heart Journal recommends controlling blood pressure if hypertensive to reduce bleeding risk, and considering proton pump inhibitor (PPI) therapy to minimize upper GI bleeding risk 6, 7, 8
- The American College of Chest Physicians recommends avoiding concomitant antiplatelet therapy unless absolutely necessary for another indication, and counseling on alcohol avoidance 1, 2, 6
Addressing Modifiable Bleeding Risk Factors
- The European Heart Journal recommends ensuring the diverticulosis has been adequately evaluated and any actively bleeding source treated before restarting anticoagulation 1, 6
- The American College of Chest Physicians recommends reinitiation of OAC after a bleeding event should be considered by a multidisciplinary team, but anticoagulation is generally appropriate once the bleeding source is controlled and contributing factors are managed 6